Welcome to our dedicated page for Pulmatrix SEC filings (Ticker: PULM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Pulmatrix often means sifting through dense disclosures just to find a single update on cash runway or Phase 2 trial costs. Annual reports exceed 200 pages, and Form 4 insider trades can land minutes after market-moving data releases. Stock Titan eliminates that pain.
Our AI-powered summaries decode every Pulmatrix filing in real time, whether you need a Pulmatrix quarterly earnings report 10-Q filing or an 8-K that details a sudden licensing agreement. Stop scrolling: the platform flags R&D spend trends, milestone payments tied to the iSPERSE pipeline, and even rescues the footnotes that explain dilution risk.
Here’s what you’ll find:
- Pulmatrix annual report 10-K simplified—AI highlights trial timelines, cash burn, and key risk factors.
- Pulmatrix insider trading Form 4 transactions—instant alerts showing executive sentiment, plus Pulmatrix Form 4 insider transactions real-time charts.
- Concise red-line comparisons of each Pulmatrix earnings report filing analysis so you can spot shifts in R&D priorities quarter over quarter.
- Clear breakdowns of the Pulmatrix proxy statement executive compensation package, formatted for quick scan.
- Pulmatrix 8-K material events explained—from FDA feedback to partnership amendments—delivered with plain-language context.
Whether you’re understanding Pulmatrix SEC documents with AI for the first time, vetting a potential investment, or monitoring Pulmatrix executive stock transactions Form 4 ahead of catalyst dates, Stock Titan gives you the full picture—no medical dictionary required.
Pulmatrix, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025, along with a corporate update. The press release is provided as Exhibit 99.1 and incorporated by reference.
Consistent with General Instruction B.2 to Item 2.02, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
Pulmatrix (PULM) filed its Q3 2025 10‑Q, reporting a narrower net loss as operating costs fell sharply while it advances a pending merger with Cullgen. For the quarter ended
Year‑to‑date, net loss was
Pulmatrix (PULM) Q2-25 10-Q highlights: revenue fell to $0 from $1.6 m YoY as development work on PUR1900 wound down. Operating expenses dropped sharply to $1.5 m (-79%), driven by a 98% reduction in R&D to $14 k after the MannKind facility divestiture and staff cuts. Net loss narrowed to $1.5 m (-73%), or -$0.42/sh versus -$1.59/sh last year. Six-month net loss improved to $3.4 m from $5.0 m.
Cash & equivalents declined to $5.8 m (Dec-24: $9.5 m) after $3.7 m operating cash burn; management believes liquidity covers ≥12 months if the Cullgen merger is not completed. Stockholders’ equity fell to $5.6 m.
Cullgen merger: approved by Pulmatrix holders on 16-Jun-25; closing now targeted by 12-Oct-25 pending CSRC and Nasdaq approvals. Pre-merger Pulmatrix investors will receive a cash dividend for net cash above $2.5 m and retain only ~3.6% pro-forma ownership. Termination fees range from $0.42 m to $8.4 m. Failure to close could push Pulmatrix toward liquidation or require new funding.
Warrant liability was re-measured to $0, creating a $67 k gain; 918 k warrants remain outstanding, many expiring July-25. No ATM sales occurred in H1-25; share count steady at 3.65 m.
FAQ
What is the current stock price of Pulmatrix (PULM)?
What is the market cap of Pulmatrix (PULM)?
